Related Experiment Video
Updated: Aug 25, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment policy of neuroendocrine small cell cancer of the cervix
X B Trinh1, J J Bogers, E A Van Marck
1University Hospital Antwerp, Department of Gynaecologic Oncology, Edegem, Belgium.
Abstract:
Small cell cancers of the cervix are very rare and aggressive tumours. It is difficult to manage these tumours. They are often diagnosed in an advanced stage and their prognosis is generally poor. There are no clinical trials, due to their rarity, that would suggest optimal treatment. The present report describes a patient with a neuroendocrine small cell cancer of the cervix Stage IB2 with a positive lymph node. The treatment consisted of radical hysterectomy and node dissection, adjuvant chemotherapy, chemoradiation and brachytherapy. Currently, after 52 months, the patient is well and free of disease. Since 1996, there has been a classification for neuroendocrine tumours (NETs) of the cervix in four categories (large cell, small cell, typical carcinoid and atypical carcinoid). The aggressive behaviour of neuroendocrine small cell cancer is demonstrated by the high percentage of early lymphatic node and vessel invasion (68 and 90%). Almost half of the patients with Stage I and II will recur with an estimated 5-year survival from 14% to a maximum of 55%. Multimodal therapy for these tumours appears to give good response but often implies severe side-effects.
Insights
Neuroendocrine small cell cervical cancer is rare and aggressive. A multimodal treatment approach, including surgery, chemotherapy, and radiation, achieved a successful outcome in a Stage IB2 patient, offering hope for similar cases.
Area of Science:
- Gynecologic Oncology
- Oncology
- Pathology
Background:
- Small cell neuroendocrine cervical cancer is a rare and aggressive malignancy.
- Optimal treatment strategies remain undefined due to tumor rarity and lack of clinical trials.
- Neuroendocrine tumors (NETs) of the cervix are classified into four categories since 1996.
Observation:
- A patient presented with Stage IB2 neuroendocrine small cell cervical cancer and a positive lymph node.
- The tumor exhibited aggressive features, including high rates of lymphatic invasion (68%) and vessel invasion (90%).
- Stage I and II disease has a high recurrence rate, with a 5-year survival ranging from 14% to 55%.
Findings:
- A multimodal treatment regimen comprising radical hysterectomy, node dissection, adjuvant chemotherapy, chemoradiation, and brachytherapy was administered.
- The patient achieved a disease-free status at 52 months post-treatment.
- Multimodal therapy shows promise but can be associated with significant side effects.
Implications:
- This case highlights the potential efficacy of aggressive multimodal therapy for neuroendocrine small cell cervical cancer.
- Further research and collaborative efforts are needed to establish standardized treatment protocols for this rare cancer.
- Improved management strategies are crucial to enhance survival rates and reduce recurrence in patients with this aggressive malignancy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...